NOVO NORDISK INC

FIASP

Manufacturer:

NOVO NORDISK INC

Fiasp HCPCS:

J1811

HCPCS Code Descriptor:

Insulin (fiasp) for administration through dme (i.e., insulin pump) per 50 units

Category:

J Code

Fiasp NDCs:

00169-3201-11

Primary Type:

Insulin

Generic/Specialty Status:

Single-Source

Route of Administration:

Injection

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Fiasp:

FIASP is a Insulin drug manufactured by NOVO NORDISK INC and administered via the Injection route of administration. The J Code: J1811 is aligned to the drug FIASP.

Fiasp is known as a fast-acting insulin, it can be used to help control blood sugar levels of patients with diabetes. It does this by increasing the uptake of sugar out of the blood stream and into cells. Fiasp is manufactured by Novo Nordisk and is not a generic medication. Patient assistance programs for this medication can be found through NovoCare.

ACCESS PRICING AND MORE BY REGISTERING

J1811 Added Date:

July 1, 2023

J1811 Effective Date:

July 1, 2023

J1811 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Fiasp billing and coding information.
Fiasp patient assistance information can be found through Novo Nordisk’s NovoCare at the URL: https://www.novocare.com/diabetes/help-with-costs/pap.html
FIASP prescribing information can be found at the link below:
Information regarding FIASP’s side effects can be found at MedlinePlus